Reminder System for Osteoporosis Care
Trial Summary
Will I have to stop taking my current medications?
The trial excludes participants who are currently being treated with an osteoporosis medication, so you would need to stop taking any osteoporosis medications to participate.
What data supports the effectiveness of the treatment Information letters for osteoporosis care?
The study on an automated osteoporosis intervention program showed that sending information letters to patients increased follow-up appointments from 14.29% in the control group to 60.19% in the intervention group, indicating that such reminders can effectively encourage patients to seek further care.12345
Is the Reminder System for Osteoporosis Care safe for humans?
How does the reminder system for osteoporosis care differ from other treatments?
The reminder system for osteoporosis care is unique because it uses electronic medical records to identify patients at high risk for fractures and sends them reminders to improve screening and follow-up care. This approach focuses on increasing patient engagement and adherence to osteoporosis management, unlike traditional treatments that primarily focus on medication.111121314
What is the purpose of this trial?
The objective of this study is to evaluate a post-fracture intervention for improving osteoporosis care in older men and women who have suffered a fracture that may indicate the presence of osteoporosis. Although osteoporosis can be identified with a bone mineral density (BMD) test, most individuals with osteoporosis are not diagnosed until they fracture. Post-fracture care often "falls between the cracks" when there is a breakdown in communication between hospital and community, or between specialists and primary care physicians. Often physicians and patients fail to make the connection between an acute fracture and osteoporosis, or the value of secondary prevention strategies. If untreated, there is an extremely high rate of additional fractures after a first osteoporotic fracture. It follows that improving BMD testing and/or treatment in appropriately identified individuals is a necessary step in optimizing post-fracture patient care. Over the next three years we will be testing and optimizing a notification procedure to physicians and/or patients relying upon fracture events reported to the provincial health service (Manitoba Health).
Research Team
William D Leslie, MD MSc
Principal Investigator
Faculty of Medicine, University of Manitoba
Eligibility Criteria
This trial is for men and women aged 50 or older in Manitoba who have recently had specific fractures (humerus, spine, hip with procedure, Colles' with procedure or cast) indicating possible osteoporosis. Excluded are non-residents, those under age 50, recent fracture patients, current osteoporosis medication users, and those with recent BMD tests.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1
Individuals meeting the fracture case definition are randomized to usual care, physician notification, or physician/patient notification. The use of appropriate post-fracture investigations and treatment is prospectively evaluated.
Phase 2
The intervention is refined and iteratively trialed for all individuals meeting the fracture case definition.
Phase 3
A recommendation for long-term maintenance of the post-fracture intervention is developed.
Follow-up
Participants are monitored for safety and effectiveness after the intervention phases.
Treatment Details
Interventions
- Information letters
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Manitoba
Lead Sponsor
The Manitoba Bone Density Program Committee
Collaborator
The Manitoba Patient Access Network Steering Committee
Collaborator